WHO ICTRP trial
To assess how safe and effective Visanne (Dienogest) is in managing pelvic pain…
CTRI/2022/04/041870 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2022/04/041870 |
|---|---|
| Public title | To assess how safe and effective Visanne (Dienogest) is in managing pelvic pain caused due to endometriosis |
| Scientific title | Phase IV study to assess the safety and effectiveness of Dienogest (Visanne®) amongst Indian women with Endometriosis, in real-world clinical practice: the VISAGE Study - VISAGE |
| Primary sponsor | Bayer Pharmaceuticals Pvt Ltd |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Observational |
| Phase | Phase 4 |
| Countries | India |
| Conditions | Health Condition 1: N809- Endometriosis, unspecified |
| Registration date | Apr 13, 2022 |
| Target size | 160 |
| Secondary IDs | 19837, V.4.0, Dated 08.03.2022;NCT04808843 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: